scispace - formally typeset
C

Chantal B.E.M. Reusken

Researcher at Erasmus University Rotterdam

Publications -  52
Citations -  13819

Chantal B.E.M. Reusken is an academic researcher from Erasmus University Rotterdam. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 22, co-authored 27 publications receiving 10420 citations. Previous affiliations of Chantal B.E.M. Reusken include Erasmus University Medical Center.

Papers
More filters
Journal ArticleDOI

Regional importation and asymmetric within-country spread of SARS-CoV-2 variants of concern in the Netherlands

TL;DR: The findings show that flight restrictions had limited effectiveness in deterring VOC introductions due to the strength of regional land travel importation risks, and highlight that robust surveillance in regions of early spread is important for providing timely information for variant detection and outbreak control.
Posted ContentDOI

Regional importation and asymmetric within-country spread of SARS-CoV-2 variants of concern in the Netherlands

TL;DR: Findings show that flight restrictions had limited effectiveness in deterring VOC introductions due to the strength of regional land travel importation risks, and highlight that robust surveillance in regions of early spread is important for providing timely information for variant detection and outbreak control.
Journal ArticleDOI

Sensitivity of Detection and Variant Typing of SARS-CoV-2 in European Laboratories

TL;DR: In this article , an external quality assessment (EQA) on the molecular detection and variant typing of SARS-CoV-2 that included 59 European laboratories in 34 countries was conducted.
Journal ArticleDOI

Differential vaccine-induced kinetics of humoral and cellular immune responses in SARS-CoV-2 naive and convalescent health care workers

TL;DR: It was found that convalescent individuals mounted higher spike-specific INF-y-secreting T cell responses and B- cell-mediated IgG responses, after receiving the Janssen vaccine or the first dose of the Pfizer vaccine, which supports the implemented single-dose mRNA booster strategy employed in the Netherlands.